Monrol is committed to serve patients around the world

We are a global radiopharmaceutical company

Slider Item
01
ECZACIBAŞI-MONROL SHAREHOLDERS SIGNED A SHARE TRANSFER AGREEMENT WITH CURIUM
02
Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity
About Us
Monrol

Nuclear
Products

01
Theranostic products with high spesific activity and purity
GO TO DETAIL
GO TO DETAIL
02
Expertise in radiopharmaceuticals supply
GO TO DETAIL
GO TO DETAIL
03
Logistic network excellence, delivering 60+ locations
GO TO DETAIL
GO TO DETAIL
Preferred partner with tailormade solutions and services for drug development
GO TO DETAIL
GO TO DETAIL
Innovation

Regarding the concept of innovation, We adopt a more holistic perception which will focus on developing innovations that include different types of innovation and that will serve the total benefit and well-being of humanity, society and the world, instead of focusing only on product innovations and commercial earning. The aim is to set out by understanding the spirit of the time and its requirements correctly.

We place great importance on innovation

As Eczacıbaşı Monrol, we aim to push the boundaries through research and development activities to enhance the quality of life for patients. We see innovation as an integral part of the DNA of radiopharmacy and believe that it forms the foundation of our future success.

GO TO DETAIL
GO TO DETAIL
Facilities & Affiliates

Our globalfootprints

We are operating more than 60 countries by having 13 facilities around the globe

GO TO DETAIL
GO TO DETAIL
PAKISTAN

Affiliate

For More
For More
MONROL UNITED ARAB EMIRATES

Affiliate

For More
For More
KUWAIT

Affiliate

For More
For More
IRAQ

Affiliate

For More
For More
TURKEY

Facility, Affiliate, Theranostic Facility

For More
For More
EGYPT

Facility, Affiliate

For More
For More
BULGARIA

Facility

For More
For More
ROMANIA

Facility

For More
For More
60+
Countries
ONE
of the biggest lutetium producers
13
Facility
+1 NEW EUROPEAN FACILITY
WILL BE ESTABLISHED
300+
EMPLOYEES
Media
Show All
Show All
News
ECZACIBAŞI-MONROL SHAREHOLDERS SIGNED A SHARE TRANSFER AGREEMENT WITH CURIUM
Read More
Read More
News
Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity
Read More
Read More
News
Monrol and FutureChem Announced a Clinical Supply Partnership
Read More
Read More
News
Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany
Read More
Read More
News
Monrol and ImaginAb Announce Supply, Manufacturing and Distribution Partnership
Read More
Read More
News
Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Telix’s Phase III ZIRCON Trial
Read More
Read More
News
Monrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium
Read More
Read More
News
MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.
Read More
Read More
News
First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey
Read More
Read More
News
Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement
Read More
Read More